Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Svas Biosana SpAMIL:SVS -0.72%77 EV-to-EBITDA is 5.32 as of Aug. 11, 2026, which is 3% below its 10-year median of 5.49. GuruFocus rates MIL:SVS with a GF Score™ of 77/100 and a GF Value™ of €10.09 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Svas Biosana SpA ranks better than 88.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Svas Biosana SpA's enterprise value is €97.5 Mil.
Svas Biosana SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €18.3 Mil. Therefore, Svas Biosana SpA's EV-to-EBITDA for today is 5.32.
The historical rank and industry rank for Svas Biosana SpA's EV-to-EBITDA or its related term are showing as below:
MIL:SVS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.89 Med: 5.49 Max: 10.09
Current: 5.32
During the past 8 years, the highest EV-to-EBITDA of Svas Biosana SpA was 10.09. The lowest was 3.89. And the median was 5.49.
MIL:SVS's EV-to-EBITDA is ranked better than 88.76% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs MIL:SVS: 5.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Svas Biosana SpA's PE Ratio (TTM) for today is calculated as:
Svas Biosana SpA's share price for today is €8.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Svas Biosana SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.286.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Svas Biosana SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Svas Biosana SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Svas Biosana SpA EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Svas Biosana SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Svas Biosana SpA's EV-to-EBITDA falls into.
Svas Biosana SpA's current Enterprise Value is €97.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Svas Biosana SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €18.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Svas Biosana SpA (MIL:SVS) has a EV-to-EBITDA of 5.32 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Svas Biosana SpA. This is near median its historical median of 5.49. Over the past decade, Svas Biosana SpA's EV-to-EBITDA has ranged from 3.89 to 10.09. According to the industry distribution chart, Svas Biosana SpA ranks #58 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 11.2%.
Is Svas Biosana SpA's EV-to-EBITDA too high?
Svas Biosana SpA's current EV-to-EBITDA of 5.32 is near median its 10-year median of 5.49. Over the past 10 years, this metric has ranged from a low of 3.89 to a high of 10.09. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. Svas Biosana SpA's value of 5.32 is 64.1% below this industry median. Based on the distribution chart, Svas Biosana SpA ranks #58 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Svas Biosana SpA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Svas Biosana SpA's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Svas Biosana SpA ranks #58 out of 516 companies for EV-to-EBITDA. This places Svas Biosana SpA in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.81. Svas Biosana SpA's value of 5.32 is 64.1% below this benchmark. Historically, Svas Biosana SpA's own EV-to-EBITDA has ranged from 3.89 to 10.09 over the past decade. While the company's 10-year median is 5.49 vs. the industry median of 14.81, Svas Biosana SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Svas Biosana SpA's current EV-to-EBITDA of 5.32 is 64.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Svas Biosana SpA. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Svas Biosana SpA's current EV-to-EBITDA is 5.32, which is near median its own 10-year median of 5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Svas Biosana SpA stock overvalued right now?
Based on GuruFocus' analysis, Svas Biosana SpA (MIL:SVS) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.09, compared to a current price of €8.26 — trading 18.1% below its estimated fair value. The current EV-to-EBITDA is 5.32, which is near median its 10-year median of 5.49 and 64.1% below the Medical Devices & Instruments industry median of 14.81. Svas Biosana SpA's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Svas Biosana SpA (MIL:SVS), the current EV-to-EBITDA is 5.32 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Svas Biosana SpA (MIL:SVS) Overvalued in 2026?
Based on GuruFocus' analysis, Svas Biosana SpA stock appears to be undervalued.
The current stock price of €8.26 is trading 18.1% below its estimated GF Value™ of €10.09.
GuruFocus considers Svas Biosana SpA to be Modestly Undervalued.
Key valuation signals for MIL:SVS:
EV-to-EBITDA: 5.32 (near median its 10-year median of 5.49)
GF Value™: €10.09 vs. price of €8.26 (18.1% below fair value)
Industry Position: 64.1% below the Medical Devices & Instruments median (#58 of 516)
No single metric tells the full story. See the MIL:SVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:SVS has been successfully added to your 
